Category: Uncategorized
-
How FDA Regulations Differ for Pharma vs Medtech vs Nutraceuticals
How FDA Regulations Differ for Pharma vs Medtech vs Nutraceuticals: A Founder’s Guide For founders entering the health and wellness space, understanding FDA regulations is crucial for successful product launches and sustainable growth. The regulatory landscape varies significantly across pharmaceutical drugs, medical devices, and nutraceuticals, each with distinct pathways, requirements, and timelines. In our experience… Read more
-
Ingredient Compliance for Emerging Nutraceutical Brands
Ingredient Compliance for Emerging Nutraceutical Brands: Building Success on Solid Foundations The nutraceutical industry presents tremendous opportunities for emerging brands willing to navigate its regulatory landscape thoughtfully. While the path to market may seem complex, understanding ingredient compliance requirements from the outset positions your brand for sustainable growth and market success. Nutraceutical brands approaching compliance… Read more
-
FDA 101 for Medtech Founders: What You Need to Know Before You Build
FDA 101 for Medtech Founders: What You Need to Know Before You Build Building a successful medtech company requires more than innovative technology and market vision. Understanding FDA basics from the earliest stages of development can make the difference between a smooth path to market and costly delays that drain resources and momentum. Medtech founders… Read more
-
QMSR vs ISO 13485: What Medtech Companies Need to Know in 2026
QMSR vs ISO 13485: What Medtech Companies Need to Know in 2026 Quality managers in the medical device industry face increasingly complex decisions about which quality management standards to implement and maintain. Two frameworks consistently emerge at the center of these discussions: the Quality Management System Regulation (QMSR) and ISO 13485. Understanding their differences, overlaps,… Read more
-
GMP Compliance for Nutraceutical Brands: Where Most Companies Fall Short
GMP Compliance for Nutraceutical Brands: Where Most Companies Fall Short The nutraceutical industry continues to experience remarkable growth, with companies racing to meet consumer demand for dietary supplements and functional foods. However, the industry consistently exhibits the same critical gaps in GMP compliance that can derail even the most promising companies. Here’s what you need… Read more
-
How to Determine Your Product’s Regulatory Classification
Understanding Your Product’s Place in the Regulatory Landscape When launching a medical device or health product, understanding your product classification serves as the foundation for every subsequent regulatory decision. This determination shapes your pathway to market, influences development timelines, and directly impacts your resource allocation strategy. In our year’s of experience working with medtech companies,… Read more
-
What Health & MedTech Founders Should Fix Before Starting M&A Conversations
What Founders Should Fix Before Starting M&A Conversations The M&A landscape for life science has never been more competitive. While strategic acquirers and private equity firms actively seek innovative medtech, pharma, and nutraceutical companies, they’re increasingly selective about the deals they make. In our experience working with companies through acquisition processes, the consistently same critical… Read more
-
Red Flags That Kill Medtech and Pharma Deals at the Due Diligence Stage
Red Flags That Kill Medtech and Pharma Deals at the Due Diligence Stage Regulatory compliance issues have derailed countless medtech M&A transactions and pharma deals just as they approached the finish line. In our experience working with acquirers and investment firms over 25+ years, we consistently see the same critical due diligence red flags emerge… Read more
-
How Unresolved FDA Findings Affect Deal Valuation
How Unresolved FDA Findings Affect Deal Valuation When pharmaceutical and medical device companies enter acquisition discussions, buyers scrutinize every aspect of regulatory compliance. Among the most critical factors that can derail a deal or significantly impact valuation is an unresolved FDA warning letter. In our experience working with companies across the medtech and pharma sectors,… Read more
-
Why Regulatory Readiness is the Most Overlooked Factor in M&A Valuations
When private equity firms and strategic acquirers evaluate life sciences companies, they typically focus on market size, intellectual property, and potential for financial performance. Yet one critical factor consistently gets relegated to the back burner: regulatory readiness. Our 25+ years of experience with medtech, pharma, and nutraceutical companies has caused us to witness how regulatory… Read more